SlideShare une entreprise Scribd logo
1  sur  13
BARBITURATEPOISONING
By
Dr. D. Sandeep
Assistant Professor
CHIPS
• Barbiturates are chemical derivatives of barbituric acid.
• Depending on their duration of action, they can be classified as long
acting (>6 hours), intermediate acting (3-6 hours) and short acting (<3
hours).
• They are classified under sedatives and hypnotics category.
• Barbiturates are frequently involved in over dosage, and are generally
taken with suicidal intent.
• The poisoning occurs after the ingestion of total dose of 3g for short
acting drugs and 5g for long acting drugs.
• The poisonous effect of barbiturates is potentiated by alcohol, narcotics,
tranquilisers and antidepressants.
MECHANISM OF POISONING
All barbiturates bind to Gamma amino butyric acid (GABA) receptors and prolong the
opening of chloride channels, thus inhibiting excitable cells of the central nervous system.
SIGNS AND SYMPTOMS
• It is characterized by progressive CNS depression culminating in paralysis of brainstem and medulla.
• Acute Poisoning - Signs and Symptoms:
• Depression,
• amnesia,
• lowered body temperature,
• depressed circulation (marked fall in blood pressure),
• respiratory embarrassment and cyanosis,
• limbs are flaccid,
• retention of urine is common,
• corneal reflexes may be absent,
• ataxia,
• deep coma,
• possible shock,
• cold extremities,
• death due to respiratory arrest (frequently associated with marked cardio-vascular depression) or pneumonia.
• Chronic Poisoning - Signs and Symptoms:
• Skin rash,
• slurred speech,
• cyanosis,
• amnesia,
• anorexia, (reduced appetite)
• emotional instability,
• ataxia and
• constipation.
MANAGEMENT OF BARBITURATE POISONING
1. CARDIO-RESPIRATORY SUPPORT:
• A clear airway is ensured by thorough suctioning and insertion of oral airway.
• The passage of barbiturates across the BBB into CNS may be facilitated during
hypoventilation and respiratory acidosis.
• If the patient is comatose, prompt intubation (without waiting for the partial oxygen to fall
to dangerously low levels) is strongly advocated .
• Dehydration is corrected by guided fluid therapy.
• If hypotension persists, IV infusion of plasma volume expanders and vasopressors are
started.
2. MEASURES TO PREVENT ABSORPTION
• a. Gastric lavage: It is done within 2-4 hours of ingestion.
• b. Activated charcoal:. 1g/Kg is administered through nasogastric tube.
• Cathartic agent like magnesium sulphate can be used along with it for further removal of
barbiturates but hypermagnesemia can occur.
3. MEASURES FOR REMOVAL OF BARBITURATES
• a. Frequent doses of activated charcoal : These adsorb the barbiturates when they
reenter the GIT through enterohepatic circulation. 1g/Kg initial dose is followed by
0.5g/kg every 2-4 hours.
• b. Forced diuresis with alkalinisation of urine:
• This is especially useful in long acting barbiturates which are largely excreted by the
kidney.
• At high rates of urine flow (by the use of diuretics), the renal clearance of barbiturates is
increased.
• Thus, it shortens the duration of coma and decreases plasma concentration of barbiturates.
• This should be avoided in older patients as it can cause pulmonary oedema,
hyponatraemia.
• In addition to diuresis, phenobarbitol excretion can be enhanced ten fold by urinary
alkalinization (pH 7.8 -8.0).
• Alkalinising urine causes ionization of phenobarbitone after its filtration into renal tubular
cells and trapping the agent, thereby inhibiting its re-absorption from renal tubules and
increasing its excretion.
• c. Haemodialysis and haemoperfusion: Is now being used extensively.
• Single six hour haemodialysis can remove more amount of barbiturate.
• Removal of short acting barbiturates is more limited because of lower plasma
concentrations and greater binding to plasma proteins.
• Supportive care: The most important aspect of management in these cases is close
observation and quality nursing care.
• Prophylactic antibiotics should be started.
• Good oral hygiene, temperature maintenance, and posture change at regular intervals.
MORPHINE/OPIOIDPOISONING
By
Dr. D. Sandeep
Assistant Professor
CHIPS
• Morphine is a pain medication belonging to opioid family.
• Naturally extracted from poppy (Papaver somniferum)
• Acts directly on CNS.
• MOST COMMON DRUG OF ABUSE
• Increases feeling of pleasure and warm, relaxation and reduced pain.
• Can be taken through various routes.
• Max effect - within 20min (IV) & 60min (oral)
• Duration of effect - 3 to 7 hours
• General use: Treatment of pain due to myocardial infraction, kidney
stones and during labor.
• Can produce other opioids like hydromorphone, heroin & oxymorphone.
Causes:
• Due to excessive consumption of any opioids (may be suicidal/intentional/accidental)
• Majorly due to drug dependence or detoxification.
• Co-ingestion with benzodiazepines or alcohol.
Signs & Symptoms:
• Respiratory depression (major reason for death)
• Hypoxia
• Miosis
• Unconsciousness
• Stupor
• Hepatic injury
• Renal failure
• Hypothermia
• Rhabdomyolysis
Mechanism of Poisoning:
• Morphine binds specifically to the neurological opioid receptors called Mu (μ)
receptors.
• Mu (μ) receptors found in cerebral cortex and thalamus.
• It evokes analgesic, sedative and euphoric effects.
• Over activation of Mu (μ) receptors occurs.
• It leads to permanent brain damage
from cerebral hypoxia or neurotoxicity.
TREATMENT
• Management of Overdose:
• Patients with Opnea need a pharmacologic or mechanical stimulus in order to breathe. For
patients with stupor, ventilation should be provided.
• Naloxone, the antidote for opioid overdose, is a competitive mu opioid–receptor
antagonist that reverses all signs of opioid intoxication.
• It is active in parenteral, intranasal, or pulmonary route of administration.
• An alternative to administration of naloxone is orotracheal intubation, a procedure that
safely ensures oxygenation and ventilation while providing protection against aspiration.
• Initial dose of naloxone for adults is 0.04 mg;
• If there is no response, the dose should be
increased every 2 minutes according to the
schedule to a maximum of 15 mg.
TREATMENT
• Clonidine: Clonidine is generally considered a safe, non-narcotic medication
used to help patients withdraw from opioids.
• It is a centrally acting alpha-2 adrenergic agonist and works to minimize the
noradrenergic hyperactivity seen in opioid withdrawal.
• For opioid withdrawal, clonidine is typically dosed at 0.1 mg to 0.3 mg orally up
to every 6 hours.
• The use of clonidine in opioid withdrawal is limited because of its hypotensive
and sedative adverse effects.
• Naltrexone. Naltrexone is a mu-receptor antagonist.
• It also antagonizes the kappa-receptor, and weakly antagonizes the delta-receptor.
• When used in conjunction with clonidine for opioid withdrawal, naltrexone is
usually dosed between 50 mg and 100 mg daily and can also be dosed 3 times
weekly.

Contenu connexe

Tendances

Tendances (20)

Schedule t -gmp_(unit-5)
Schedule t -gmp_(unit-5)Schedule t -gmp_(unit-5)
Schedule t -gmp_(unit-5)
 
Medicinal chemistry of Anti viral agents
 Medicinal chemistry of Anti viral agents  Medicinal chemistry of Anti viral agents
Medicinal chemistry of Anti viral agents
 
Bonded vs non bonded laboratories
Bonded vs non bonded laboratoriesBonded vs non bonded laboratories
Bonded vs non bonded laboratories
 
Anti-tubercular agents
Anti-tubercular agentsAnti-tubercular agents
Anti-tubercular agents
 
Antibiotics - Medicinal chemistry
Antibiotics - Medicinal chemistry Antibiotics - Medicinal chemistry
Antibiotics - Medicinal chemistry
 
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...
 
Antileprotic drugs
Antileprotic drugsAntileprotic drugs
Antileprotic drugs
 
Drugs as digestants and carminatives.
Drugs as digestants and carminatives.Drugs as digestants and carminatives.
Drugs as digestants and carminatives.
 
Nonlinear Pharmacokinetics
Nonlinear PharmacokineticsNonlinear Pharmacokinetics
Nonlinear Pharmacokinetics
 
Protein binding of drug.ppt
Protein binding of drug.pptProtein binding of drug.ppt
Protein binding of drug.ppt
 
GENERAL PRINCIPLES OF TREATMENT OF POISONING
GENERAL PRINCIPLES OF TREATMENT OF POISONINGGENERAL PRINCIPLES OF TREATMENT OF POISONING
GENERAL PRINCIPLES OF TREATMENT OF POISONING
 
Factors Affecting Protein-Binding of Drugs
Factors Affecting Protein-Binding of DrugsFactors Affecting Protein-Binding of Drugs
Factors Affecting Protein-Binding of Drugs
 
Medicinal Chemistry of Diuretics
Medicinal Chemistry of DiureticsMedicinal Chemistry of Diuretics
Medicinal Chemistry of Diuretics
 
Barbiturate poisoning (pharmacology)
Barbiturate poisoning  (pharmacology)Barbiturate poisoning  (pharmacology)
Barbiturate poisoning (pharmacology)
 
Regulatory issues regulations in india asu
Regulatory issues   regulations in india asuRegulatory issues   regulations in india asu
Regulatory issues regulations in india asu
 
Chronopharmacology
ChronopharmacologyChronopharmacology
Chronopharmacology
 
Antiulcer drugs
Antiulcer drugsAntiulcer drugs
Antiulcer drugs
 
Bio assays of insulin
Bio assays of insulinBio assays of insulin
Bio assays of insulin
 
Aminoglycosides(medicinal chemistry by p.ravisankar)
Aminoglycosides(medicinal chemistry by p.ravisankar)Aminoglycosides(medicinal chemistry by p.ravisankar)
Aminoglycosides(medicinal chemistry by p.ravisankar)
 
Absorption of drugs from non per os extravascular administration
Absorption of drugs from non per os extravascular administrationAbsorption of drugs from non per os extravascular administration
Absorption of drugs from non per os extravascular administration
 

Similaire à Barbiturate & Morphine poisoning

SEADTIVE HYPNOTIC DRUGS PPT 2.pdf hghhhhhh we
SEADTIVE HYPNOTIC DRUGS  PPT 2.pdf hghhhhhh weSEADTIVE HYPNOTIC DRUGS  PPT 2.pdf hghhhhhh we
SEADTIVE HYPNOTIC DRUGS PPT 2.pdf hghhhhhh we
epicsoundever
 
02intravenousinductionagents-160226094535 (1) (1).pdf
02intravenousinductionagents-160226094535 (1) (1).pdf02intravenousinductionagents-160226094535 (1) (1).pdf
02intravenousinductionagents-160226094535 (1) (1).pdf
DharmarajNBadyankal
 

Similaire à Barbiturate & Morphine poisoning (20)

Sedatives Hypnotics Pharmacology
Sedatives Hypnotics PharmacologySedatives Hypnotics Pharmacology
Sedatives Hypnotics Pharmacology
 
Sedation, Analgesia & Delirium.pptx
Sedation, Analgesia & Delirium.pptxSedation, Analgesia & Delirium.pptx
Sedation, Analgesia & Delirium.pptx
 
Induction Agents - Propofol, Sodium Thiopental, Ketamine,
Induction Agents - Propofol, Sodium Thiopental, Ketamine, Induction Agents - Propofol, Sodium Thiopental, Ketamine,
Induction Agents - Propofol, Sodium Thiopental, Ketamine,
 
Muscle releaxent toxicity
Muscle releaxent toxicityMuscle releaxent toxicity
Muscle releaxent toxicity
 
CNS STIMULANTS
CNS STIMULANTS CNS STIMULANTS
CNS STIMULANTS
 
propofol.pptx
propofol.pptxpropofol.pptx
propofol.pptx
 
Sedatives and hypnotics
Sedatives and hypnoticsSedatives and hypnotics
Sedatives and hypnotics
 
Premedicant drugs in Anesthesia
Premedicant drugs in AnesthesiaPremedicant drugs in Anesthesia
Premedicant drugs in Anesthesia
 
Analegesia.pptx
Analegesia.pptxAnalegesia.pptx
Analegesia.pptx
 
Lecture about sedative hypnotic drugs
Lecture about sedative  hypnotic drugsLecture about sedative  hypnotic drugs
Lecture about sedative hypnotic drugs
 
Parasympatholytics/ Anticholinergic/ Muscarinic blockers/ Atropine
Parasympatholytics/ Anticholinergic/ Muscarinic blockers/ AtropineParasympatholytics/ Anticholinergic/ Muscarinic blockers/ Atropine
Parasympatholytics/ Anticholinergic/ Muscarinic blockers/ Atropine
 
Anticholinergic Drugs
Anticholinergic DrugsAnticholinergic Drugs
Anticholinergic Drugs
 
Drugs acting on the central nervous system
Drugs acting on the central nervous systemDrugs acting on the central nervous system
Drugs acting on the central nervous system
 
Anesthetic medications
Anesthetic medicationsAnesthetic medications
Anesthetic medications
 
SEADTIVE HYPNOTIC DRUGS PPT 2.pdf hghhhhhh we
SEADTIVE HYPNOTIC DRUGS  PPT 2.pdf hghhhhhh weSEADTIVE HYPNOTIC DRUGS  PPT 2.pdf hghhhhhh we
SEADTIVE HYPNOTIC DRUGS PPT 2.pdf hghhhhhh we
 
Clinical use of neuromuscular blocking agents in critically ill patients - NMDA
Clinical use of neuromuscular blocking agents in critically ill patients - NMDAClinical use of neuromuscular blocking agents in critically ill patients - NMDA
Clinical use of neuromuscular blocking agents in critically ill patients - NMDA
 
CNS depressants poisoning
CNS depressants poisoningCNS depressants poisoning
CNS depressants poisoning
 
02intravenousinductionagents-160226094535 (1) (1).pdf
02intravenousinductionagents-160226094535 (1) (1).pdf02intravenousinductionagents-160226094535 (1) (1).pdf
02intravenousinductionagents-160226094535 (1) (1).pdf
 
Barbiturate poisoning
Barbiturate poisoningBarbiturate poisoning
Barbiturate poisoning
 
Antiemetic's _ Ondansetron
Antiemetic's  _ OndansetronAntiemetic's  _ Ondansetron
Antiemetic's _ Ondansetron
 

Dernier

Formation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disksFormation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disks
Sérgio Sacani
 
Pests of mustard_Identification_Management_Dr.UPR.pdf
Pests of mustard_Identification_Management_Dr.UPR.pdfPests of mustard_Identification_Management_Dr.UPR.pdf
Pests of mustard_Identification_Management_Dr.UPR.pdf
PirithiRaju
 
Presentation Vikram Lander by Vedansh Gupta.pptx
Presentation Vikram Lander by Vedansh Gupta.pptxPresentation Vikram Lander by Vedansh Gupta.pptx
Presentation Vikram Lander by Vedansh Gupta.pptx
gindu3009
 
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 bAsymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Sérgio Sacani
 
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdfPests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
PirithiRaju
 
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Lokesh Kothari
 

Dernier (20)

Formation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disksFormation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disks
 
Chromatin Structure | EUCHROMATIN | HETEROCHROMATIN
Chromatin Structure | EUCHROMATIN | HETEROCHROMATINChromatin Structure | EUCHROMATIN | HETEROCHROMATIN
Chromatin Structure | EUCHROMATIN | HETEROCHROMATIN
 
Stunning ➥8448380779▻ Call Girls In Panchshil Enclave Delhi NCR
Stunning ➥8448380779▻ Call Girls In Panchshil Enclave Delhi NCRStunning ➥8448380779▻ Call Girls In Panchshil Enclave Delhi NCR
Stunning ➥8448380779▻ Call Girls In Panchshil Enclave Delhi NCR
 
Pests of mustard_Identification_Management_Dr.UPR.pdf
Pests of mustard_Identification_Management_Dr.UPR.pdfPests of mustard_Identification_Management_Dr.UPR.pdf
Pests of mustard_Identification_Management_Dr.UPR.pdf
 
GBSN - Biochemistry (Unit 1)
GBSN - Biochemistry (Unit 1)GBSN - Biochemistry (Unit 1)
GBSN - Biochemistry (Unit 1)
 
Forensic Biology & Its biological significance.pdf
Forensic Biology & Its biological significance.pdfForensic Biology & Its biological significance.pdf
Forensic Biology & Its biological significance.pdf
 
Presentation Vikram Lander by Vedansh Gupta.pptx
Presentation Vikram Lander by Vedansh Gupta.pptxPresentation Vikram Lander by Vedansh Gupta.pptx
Presentation Vikram Lander by Vedansh Gupta.pptx
 
GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)GBSN - Microbiology (Unit 1)
GBSN - Microbiology (Unit 1)
 
Botany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdfBotany 4th semester series (krishna).pdf
Botany 4th semester series (krishna).pdf
 
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 bAsymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
Asymmetry in the atmosphere of the ultra-hot Jupiter WASP-76 b
 
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdfPests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
 
Natural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsNatural Polymer Based Nanomaterials
Natural Polymer Based Nanomaterials
 
GBSN - Microbiology (Unit 2)
GBSN - Microbiology (Unit 2)GBSN - Microbiology (Unit 2)
GBSN - Microbiology (Unit 2)
 
Recombination DNA Technology (Nucleic Acid Hybridization )
Recombination DNA Technology (Nucleic Acid Hybridization )Recombination DNA Technology (Nucleic Acid Hybridization )
Recombination DNA Technology (Nucleic Acid Hybridization )
 
Green chemistry and Sustainable development.pptx
Green chemistry  and Sustainable development.pptxGreen chemistry  and Sustainable development.pptx
Green chemistry and Sustainable development.pptx
 
CELL -Structural and Functional unit of life.pdf
CELL -Structural and Functional unit of life.pdfCELL -Structural and Functional unit of life.pdf
CELL -Structural and Functional unit of life.pdf
 
Isotopic evidence of long-lived volcanism on Io
Isotopic evidence of long-lived volcanism on IoIsotopic evidence of long-lived volcanism on Io
Isotopic evidence of long-lived volcanism on Io
 
Raman spectroscopy.pptx M Pharm, M Sc, Advanced Spectral Analysis
Raman spectroscopy.pptx M Pharm, M Sc, Advanced Spectral AnalysisRaman spectroscopy.pptx M Pharm, M Sc, Advanced Spectral Analysis
Raman spectroscopy.pptx M Pharm, M Sc, Advanced Spectral Analysis
 
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
Labelling Requirements and Label Claims for Dietary Supplements and Recommend...
 
Chemistry 4th semester series (krishna).pdf
Chemistry 4th semester series (krishna).pdfChemistry 4th semester series (krishna).pdf
Chemistry 4th semester series (krishna).pdf
 

Barbiturate & Morphine poisoning

  • 2. • Barbiturates are chemical derivatives of barbituric acid. • Depending on their duration of action, they can be classified as long acting (>6 hours), intermediate acting (3-6 hours) and short acting (<3 hours). • They are classified under sedatives and hypnotics category. • Barbiturates are frequently involved in over dosage, and are generally taken with suicidal intent. • The poisoning occurs after the ingestion of total dose of 3g for short acting drugs and 5g for long acting drugs. • The poisonous effect of barbiturates is potentiated by alcohol, narcotics, tranquilisers and antidepressants.
  • 3. MECHANISM OF POISONING All barbiturates bind to Gamma amino butyric acid (GABA) receptors and prolong the opening of chloride channels, thus inhibiting excitable cells of the central nervous system.
  • 4. SIGNS AND SYMPTOMS • It is characterized by progressive CNS depression culminating in paralysis of brainstem and medulla. • Acute Poisoning - Signs and Symptoms: • Depression, • amnesia, • lowered body temperature, • depressed circulation (marked fall in blood pressure), • respiratory embarrassment and cyanosis, • limbs are flaccid, • retention of urine is common, • corneal reflexes may be absent, • ataxia, • deep coma, • possible shock, • cold extremities, • death due to respiratory arrest (frequently associated with marked cardio-vascular depression) or pneumonia.
  • 5. • Chronic Poisoning - Signs and Symptoms: • Skin rash, • slurred speech, • cyanosis, • amnesia, • anorexia, (reduced appetite) • emotional instability, • ataxia and • constipation. MANAGEMENT OF BARBITURATE POISONING 1. CARDIO-RESPIRATORY SUPPORT: • A clear airway is ensured by thorough suctioning and insertion of oral airway. • The passage of barbiturates across the BBB into CNS may be facilitated during hypoventilation and respiratory acidosis. • If the patient is comatose, prompt intubation (without waiting for the partial oxygen to fall to dangerously low levels) is strongly advocated . • Dehydration is corrected by guided fluid therapy. • If hypotension persists, IV infusion of plasma volume expanders and vasopressors are started.
  • 6. 2. MEASURES TO PREVENT ABSORPTION • a. Gastric lavage: It is done within 2-4 hours of ingestion. • b. Activated charcoal:. 1g/Kg is administered through nasogastric tube. • Cathartic agent like magnesium sulphate can be used along with it for further removal of barbiturates but hypermagnesemia can occur. 3. MEASURES FOR REMOVAL OF BARBITURATES • a. Frequent doses of activated charcoal : These adsorb the barbiturates when they reenter the GIT through enterohepatic circulation. 1g/Kg initial dose is followed by 0.5g/kg every 2-4 hours. • b. Forced diuresis with alkalinisation of urine: • This is especially useful in long acting barbiturates which are largely excreted by the kidney. • At high rates of urine flow (by the use of diuretics), the renal clearance of barbiturates is increased. • Thus, it shortens the duration of coma and decreases plasma concentration of barbiturates.
  • 7. • This should be avoided in older patients as it can cause pulmonary oedema, hyponatraemia. • In addition to diuresis, phenobarbitol excretion can be enhanced ten fold by urinary alkalinization (pH 7.8 -8.0). • Alkalinising urine causes ionization of phenobarbitone after its filtration into renal tubular cells and trapping the agent, thereby inhibiting its re-absorption from renal tubules and increasing its excretion. • c. Haemodialysis and haemoperfusion: Is now being used extensively. • Single six hour haemodialysis can remove more amount of barbiturate. • Removal of short acting barbiturates is more limited because of lower plasma concentrations and greater binding to plasma proteins. • Supportive care: The most important aspect of management in these cases is close observation and quality nursing care. • Prophylactic antibiotics should be started. • Good oral hygiene, temperature maintenance, and posture change at regular intervals.
  • 9. • Morphine is a pain medication belonging to opioid family. • Naturally extracted from poppy (Papaver somniferum) • Acts directly on CNS. • MOST COMMON DRUG OF ABUSE • Increases feeling of pleasure and warm, relaxation and reduced pain. • Can be taken through various routes. • Max effect - within 20min (IV) & 60min (oral) • Duration of effect - 3 to 7 hours • General use: Treatment of pain due to myocardial infraction, kidney stones and during labor. • Can produce other opioids like hydromorphone, heroin & oxymorphone.
  • 10. Causes: • Due to excessive consumption of any opioids (may be suicidal/intentional/accidental) • Majorly due to drug dependence or detoxification. • Co-ingestion with benzodiazepines or alcohol. Signs & Symptoms: • Respiratory depression (major reason for death) • Hypoxia • Miosis • Unconsciousness • Stupor • Hepatic injury • Renal failure • Hypothermia • Rhabdomyolysis
  • 11. Mechanism of Poisoning: • Morphine binds specifically to the neurological opioid receptors called Mu (μ) receptors. • Mu (μ) receptors found in cerebral cortex and thalamus. • It evokes analgesic, sedative and euphoric effects. • Over activation of Mu (μ) receptors occurs. • It leads to permanent brain damage from cerebral hypoxia or neurotoxicity.
  • 12. TREATMENT • Management of Overdose: • Patients with Opnea need a pharmacologic or mechanical stimulus in order to breathe. For patients with stupor, ventilation should be provided. • Naloxone, the antidote for opioid overdose, is a competitive mu opioid–receptor antagonist that reverses all signs of opioid intoxication. • It is active in parenteral, intranasal, or pulmonary route of administration. • An alternative to administration of naloxone is orotracheal intubation, a procedure that safely ensures oxygenation and ventilation while providing protection against aspiration. • Initial dose of naloxone for adults is 0.04 mg; • If there is no response, the dose should be increased every 2 minutes according to the schedule to a maximum of 15 mg.
  • 13. TREATMENT • Clonidine: Clonidine is generally considered a safe, non-narcotic medication used to help patients withdraw from opioids. • It is a centrally acting alpha-2 adrenergic agonist and works to minimize the noradrenergic hyperactivity seen in opioid withdrawal. • For opioid withdrawal, clonidine is typically dosed at 0.1 mg to 0.3 mg orally up to every 6 hours. • The use of clonidine in opioid withdrawal is limited because of its hypotensive and sedative adverse effects. • Naltrexone. Naltrexone is a mu-receptor antagonist. • It also antagonizes the kappa-receptor, and weakly antagonizes the delta-receptor. • When used in conjunction with clonidine for opioid withdrawal, naltrexone is usually dosed between 50 mg and 100 mg daily and can also be dosed 3 times weekly.